EXHIBIT 99.1 MiNK Reports Fourth Quarter and Year-End 2023 Results Launched and enrolling Phase 2 trial of allo-iNKTs with botensilimab/balstilimab and chemotherapy in second-line gastroesophageal cancers Announced collaboration with Immunoscape for development of TCR-based therapies Published clinical data in Nature Communications and Oncogene demonstrating clinical activity of allo- iNKTs, agenT-797, in solid tumors and severe acute respiratory distress NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- MiNK Th ...